

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 8, 2019

**Conformis, Inc.**

(Exact Name of Company as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-37474**  
(Commission  
File Number)

**56-2463152**  
(IRS Employer  
Identification No.)

**600 Technology Park Drive**  
**Billerica, MA 01821**  
(Address of Principal Executive Offices) (Zip Code)

Company's telephone number, including area code: **(781) 345-9001**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

## Item 2.02 Results of Operations and Financial Condition

On January 8, 2019, Conformis, Inc. issued a press release announcing its selected preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2018. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

The information furnished under this Item 2.02, including the press release attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.

## Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">99.1*</a>	<a href="#">Press Release of ConforMIS, Inc., dated January 8, 2019</a>

\*Furnished herewith

---



## Conformis Reports Preliminary Fourth Quarter and Year-End 2018 Revenue Results

BILLERICA, Mass. and SAN FRANCISCO, Ca., January 8, 2019 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants designed to fit each patient's unique anatomy, today announced preliminary, unaudited, revenue results for the fourth quarter and the year ended December 31, 2018.

### Expected Q4 Summary:

- Total revenue of approximately \$22.0 million, up 6% year-over-year on a reported basis and 7% on a constant currency basis
- Product revenue of approximately \$21.9 million, up 7% year-over-year on a reported and constant currency basis
  - U.S. product revenue of approximately \$19.4 million, up 10% year-over-year on a reported basis
  - Rest of World product revenue of approximately \$2.5 million, down 14% year-over-year on a reported basis and 12% on a constant currency basis

### Expected 2018 Summary:

- Total revenue of approximately \$89.8 million, up 15% year-over-year on a reported basis, including a royalty settlement of \$10.5 million, and 14% on a constant currency basis
- Product revenue of approximately \$78.6 million, up 2% year-over-year on a reported basis and 1% on a constant currency basis
  - U.S. product revenue of approximately \$68.1 million, up 6% year-over-year
  - Rest of World product revenue of approximately \$10.6 million, down 17% year-over-year on a reported basis and 22% on a constant currency basis

These preliminary results are being provided in advance of the Company's presentation at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco. Mark Augusti, the Company's President and Chief Executive Officer, will present at the conference at 8:30 a.m. PT on Thursday, January 10, 2019.

The preliminary unaudited revenue results described in this press release are estimates only and are subject to revision. The Company expects to report its full financial results, including gross margin, for the fourth quarter and the year ended 2018 on February 6, 2019.

### About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. Conformis offers a broad line of customized knee and hip implants and customized pre-sterilized, single-use instruments delivered in a single package to the hospital. In clinical studies, Conformis iTotals CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover customized implants and customized patient-specific instrumentation for all major joints.

For more information, visit [www.conformis.com](http://www.conformis.com). To receive future releases in e-mail alerts, sign up at [ir.conformis.com](http://ir.conformis.com).

### Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our product launches, and our financial position and results, ability to

---

achieve profitability, total revenue, product revenue, gross margin, operations, operating expenses, and financing plans, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including whether our cash resources will be sufficient to fund our continuing operations for the periods anticipated; risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations; risks related to the impact of our reduction in force; risks associated with our ability or inability to satisfy loan covenants; and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

**CONTACT:**

Investor Relations  
ir@conformis.com  
(781) 374-5598